» Articles » PMID: 19967438

The PINK1/Parkin Pathway: a Mitochondrial Quality Control System?

Overview
Publisher Springer
Date 2009 Dec 8
PMID 19967438
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Significant insight into the mechanisms that contribute to dopaminergic neurodegeneration in Parkinson disease has been gained from the analysis of genes linked to rare heritable forms of parkinsonism such as PINK1 and parkin, loss-of-function mutations of which cause autosomal recessive parkinsonism. PINK1 encodes a mitochondrially targeted Ser/Thr kinase and parkin encodes a ubiquitin-protein ligase. Functional studies of PINK1 and Parkin in animal and cellular model systems have shown that both proteins play important roles in maintaining mitochondrial integrity. Genetic studies of PINK1 and Parkin orthologs in flies have shown that PINK1 acts upstream from Parkin in a common pathway that appears to regulate mitochondrial morphology. Mitochondrial morphology is regulated by mitochondrial fission and fusion-promoting proteins, and is important in a variety of contexts, including mitochondrial trafficking and mitochondrial quality control. In particular, mitochondrial fission appears to promote the segregation of terminally dysfunctional mitochondria for degradation in the lysosome through a process termed mitophagy. Recent work has shown that Parkin promotes the degradation of dysfunctional mitochondria in vertebrate cell culture. Here we postulate a model whereby the PINK1/Parkin pathway regulates mitochondrial dynamics in an effort to promote the turnover of damaged mitochondria.

Citing Articles

Examining Sporadic Cancer Mutations Uncovers a Set of Genes Involved in Mitochondrial Maintenance.

Moreno A, Taffet A, Tjahjono E, Anderson Q, Kirienko N Genes (Basel). 2023; 14(5).

PMID: 37239369 PMC: 10218105. DOI: 10.3390/genes14051009.


Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation.

Lu Y, Li Z, Zhang S, Zhang T, Liu Y, Zhang L Theranostics. 2023; 13(2):736-766.

PMID: 36632220 PMC: 9830443. DOI: 10.7150/thno.79876.


Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson's Disease.

Blagov A, Goncharov A, Babich O, Larina V, Orekhov A, Melnichenko A Pharmaceutics. 2022; 14(11).

PMID: 36432705 PMC: 9696222. DOI: 10.3390/pharmaceutics14112514.


Mitigation of age-dependent accumulation of defective mitochondrial genomes.

Tsai P, Korotkevich E, OFarrell P Proc Natl Acad Sci U S A. 2022; 119(31):e2119009119.

PMID: 35881807 PMC: 9351377. DOI: 10.1073/pnas.2119009119.


BMI1 Silencing Induces Mitochondrial Dysfunction in Lung Epithelial Cells Exposed to Hyperoxia.

Hernandez-Cuervo H, Soundararajan R, Patil S, Breitzig M, Alleyn M, Galam L Front Physiol. 2022; 13:814510.

PMID: 35431986 PMC: 9005903. DOI: 10.3389/fphys.2022.814510.


References
1.
Lutz A, Exner N, Fett M, Schlehe J, Kloos K, Lammermann K . Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem. 2009; 284(34):22938-51. PMC: 2755701. DOI: 10.1074/jbc.M109.035774. View

2.
Abou-Sleiman P, Muqit M, Wood N . Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006; 7(3):207-19. DOI: 10.1038/nrn1868. View

3.
Narendra D, Tanaka A, Suen D, Youle R . Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008; 183(5):795-803. PMC: 2592826. DOI: 10.1083/jcb.200809125. View

4.
Zhou C, Huang Y, Shao Y, May J, Prou D, Perier C . The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A. 2008; 105(33):12022-7. PMC: 2575334. DOI: 10.1073/pnas.0802814105. View

5.
Sandebring A, Thomas K, Beilina A, van der Brug M, Cleland M, Ahmad R . Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS One. 2009; 4(5):e5701. PMC: 2683574. DOI: 10.1371/journal.pone.0005701. View